Repligen Reports Third Quarter 2014 Financial Results
Product Revenue Increases 24% to $15.2 Million Product Gross Profit Increases 26% to $8.2 Million Conference Call and Webcast Today at 8:30 a.m. EST WALTHAM, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for its third quarter ended September 30, 2014. The Company's financial and business highlights for the third quarter and year-to-date follow, as well as updated financial guidance for the year 2014. Third Quarter Financial Highlights: Product revenue for the third quarter of 2014 was $15.2 million, an increase of 24%, compared to $12.2 million in product revenue for the third quarter of 2013. Total revenue for the third quarter of 2014 was $15.3 million, compared to $18.8 million for the third quarter of 2013. The 2013 quarter included $6.6 million in royalty and other revenue, of which $4.8 million was royalty revenue from Bristol-Myers Squibb based on its U.S. sales of Orencia ® under an agreement that expired on December